WFG Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

WFG Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-92	Closed	-$6K	–	2095
2014 Q1	$6K	Buy	+92	New	+$6.76K	﹤0.01%	1601

Other funds holding CLVS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CPCM

Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

WFG Advisors's CLVS Position: Q2 2014 in Review

WFG Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2014, closing a stake of 92 shares — an estimated $6K sold.

WFG Advisors first reported a position in CLVS in Q1 2014 and held it in 1 quarter. The position peaked at $6K in Q1 2014. 140 funds tracked by Wall St. Rank hold CLVS as of Q2 2014.

WFG Advisors reported no remaining Clovis Oncology, Inc. position as of Q2 2014 after selling out during the quarter.
WFG Advisors sold 92 Clovis Oncology, Inc. shares in Q2 2014, an estimated $6K.
WFG Advisors first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 1 quarter.
WFG Advisors's Clovis Oncology, Inc. position peaked at $6K in Q1 2014.
140 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2014.

Based on WFG Advisors's 13F filing for Q2 2014, filed 12 Aug 2014.